Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 128, Issue -, Pages 101-114Publisher
ELSEVIER
DOI: 10.1016/j.addr.2017.12.015
Keywords
Microfluidic chips; Polymer; Lipid; Drug delivery; Precise control; Core/shell; Mass production
Categories
Funding
- Ministry of Science and Technology of China [2013YQ190467]
- Chinese Academy of Sciences [XDA09030305]
- National Science Foundation of China [81361140345, 51373043, 21535001]
Ask authors/readers for more resources
Microfluidic chips allow the rapid production of a library of nanoparticles (NPs) with distinct properties by changing the precursors and the flow rates, significantly decreasing the time for screening optimal formulation as carriers for drug delivery compared to conventional methods. The batch-to-batch reproducibility which is essential for clinical translation is achieved by precisely controlling the precursors and the flow rate, regardless of operators. Poly (lactic-co-glycolic acid) (PLGA) is the most widely used Food and Drug Administration (FDA)-approved biodegradable polymers. Researchers often combine PLGA with lipids or amphiphilic molecules to assemble into a core/shell structure to exploit the potential of PLGA-based NPs as powerful carriers for cancer-related drug delivery. In this review, we discuss the advantages associated with microfluidic chips for producing PLGA-based functional nanocomplexes for drug delivery. These laboratory-based methods can readily scale up to provide sufficient amount of PLGA-based NPs in microfluidic chips for clinical studies and industrial-scale production. (C) 2017 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available